Caas Capital Management LP bought a new position in iRhythm Technologies (NASDAQ:IRTC - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 2,502 shares of the company's stock, valued at approximately $262,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in shares of iRhythm Technologies by 30,928.6% in the 1st quarter. GAMMA Investing LLC now owns 8,688 shares of the company's stock worth $909,000 after purchasing an additional 8,660 shares during the period. SG Americas Securities LLC boosted its holdings in shares of iRhythm Technologies by 95.6% in the 1st quarter. SG Americas Securities LLC now owns 8,427 shares of the company's stock worth $882,000 after purchasing an additional 4,119 shares during the period. Invesco Ltd. boosted its holdings in shares of iRhythm Technologies by 1.1% in the 4th quarter. Invesco Ltd. now owns 19,200 shares of the company's stock worth $1,731,000 after purchasing an additional 207 shares during the period. PNC Financial Services Group Inc. boosted its holdings in shares of iRhythm Technologies by 32.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,980 shares of the company's stock worth $449,000 after purchasing an additional 1,215 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in iRhythm Technologies by 13.6% during the 4th quarter. Ameriprise Financial Inc. now owns 71,254 shares of the company's stock valued at $6,425,000 after acquiring an additional 8,528 shares during the period.
Insider Transactions at iRhythm Technologies
In other news, EVP Minang Turakhia sold 1,420 shares of the business's stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $145.41, for a total value of $206,482.20. Following the completion of the transaction, the executive vice president directly owned 41,393 shares of the company's stock, valued at approximately $6,018,956.13. The trade was a 3.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Daniel G. Wilson sold 3,000 shares of the company's stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $150.00, for a total value of $450,000.00. Following the transaction, the chief financial officer directly owned 40,307 shares in the company, valued at $6,046,050. This represents a 6.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 5,356 shares of company stock valued at $796,882. Corporate insiders own 1.10% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on IRTC shares. Wall Street Zen downgraded iRhythm Technologies from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. Citigroup upped their price objective on iRhythm Technologies from $130.00 to $167.00 and gave the company a "buy" rating in a research report on Thursday, May 22nd. Canaccord Genuity Group cut their price objective on iRhythm Technologies from $152.00 to $139.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company raised iRhythm Technologies from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $104.00 to $130.00 in a research report on Friday, May 2nd. Finally, Needham & Company LLC lifted their target price on iRhythm Technologies from $138.00 to $151.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $138.60.
Get Our Latest Analysis on IRTC
iRhythm Technologies Trading Up 1.4%
IRTC opened at $134.71 on Friday. The firm has a market cap of $4.30 billion, a price-to-earnings ratio of -42.90 and a beta of 1.41. The company has a current ratio of 5.71, a quick ratio of 5.58 and a debt-to-equity ratio of 7.47. iRhythm Technologies has a 12 month low of $55.92 and a 12 month high of $157.13. The stock has a fifty day moving average price of $142.96 and a 200-day moving average price of $117.31.
iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.06). The company had revenue of $158.68 million during the quarter, compared to the consensus estimate of $153.39 million. iRhythm Technologies had a negative return on equity of 101.04% and a negative net margin of 15.90%. The company's revenue was up 20.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.23) earnings per share. As a group, equities research analysts anticipate that iRhythm Technologies will post -1.98 earnings per share for the current fiscal year.
iRhythm Technologies Company Profile
(
Free Report)
iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iRhythm Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRhythm Technologies wasn't on the list.
While iRhythm Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.